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Background. Platelet-activating factor (PAF) may be involved in
the pathogenesis of steroid-responsive nephrotic syndrome
(SRNS). PAF is degraded to inactive products by PAF acetylhy-
drolase. We have investigated whether PAF acetylhydrolase gene
mutation is involved in SRNS in Japanese children.
Methods. We identified a point mutation in the PAF acetylhy-
drolase gene (G994T) using the polymerase chain reaction in 101
Japanese children with SRNS and 100 healthy Japanese.
Results. There was no difference in the genotype and allele
frequencies between patients with SRNS and normal controls.
The mean number of relapses during the first year after onset was
significantly higher in the 26 patients who were heterozygous for
the mutant allele (GT) than in 75 wild-type homozygotes (GG)
(2.61 6 1.98 vs. 1.33 6 1.35; P 5 0.0019).
Conclusions. We conclude that analysis of the PAF acetylhy-
drolase gene mutation at position 994 in Japanese children with
SRNS allows the identification of patients who are more likely to
have a disease relapse.
Platelet-activating factor (PAF; 1-0-alkyl-2-acetyl-sn-
glycero-3-phosphocholine) is a phospholipid mediator that
has been shown to have a variety of biological activities
[1–3]. It appears to function both in normal physiological
events and to mediate pathological responses, particularly
allergy and inflammation. There is increasing evidence that
PAF is involved in the pathogenesis of glomerulonephritis
and nephrotic syndrome [4–7]. PAF is produced by inflam-
matory cells, endothelial cells, and glomerular mesangial
cells [5, 6, 8, 9]. It possesses a multitude of biological effects
pertinent to glomerular injury including chemotaxis and
activation of leukocytes, complement activation, and con-
traction and stimulation of glomerular mesangial cells to
produce prostaglandins and oxygen radicals [5, 10]. Fur-
thermore, PAF also enhances vascular permeability and
induces proteinuria [7, 10, 11].
The PAF concentration is tightly regulated at both the
synthetic and degradative levels in order to avoid inappro-
priately high concentrations [1, 12, 13]. PAF is degraded to
inactive products by hydrolysis of the acetyl group at the
sn-2 position, to produce the biologically inactive products
lyso-PAF and acetate. This reaction is catalyzed by PAF
acetylhydrolase. Alterations in PAF acetylhydrolase activity
have been reported in several disease states and may
contribute to the pathogenesis of these conditions [14, 15].
Miwa et al reported an inherited form of PAF acetylhy-
drolase deficiency [16]. This autosomal recessive trait has
only been observed in the Japanese population. Recently,
Stafforini et al demonstrated that the PAF acetylhydrolase
deficiency was the result of a point mutation near the active
site of PAF acetylhydrolase (G to T transversion, at posi-
tion 994 in exon 9) [17]. In patients who are homozygous
for the mutation, enzymatic activity is completely abol-
ished, while heterozygotes have reduced activity. An inher-
ited deficiency of PAF acetylhydrolase activity has been
associated with severe asthma in Japanese children [16].
Steroid-responsive nephrotic syndrome (SRNS) is often
associated with allergic disorders [18]. We therefore postu-
lated that the PAF acetylhydrolase gene mutation may play
an important role in the pathogenesis of SRNS. In order to
test this hypothesis, we investigated the effect of this
mutation on the incidence of and relapse from SRNS.
METHODS
Patients. The following methods are in accordance with
the ethical standards for human experimentation stipulated
by the Ethics Committee of Kobe University Hospital.
Informed consent was obtained from each individual.
Patients and controls
We studied 101 consecutive Japanese patients with
SRNS, who visited 14 hospitals in Hyogo and Osaka
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prefectures between January and September 1997. The age
of onset of nephrotic syndrome in all the patients was less
than 16 years. All the patients were followed for at least one
year after disease onset. Thirty patients with frequent
relapses underwent renal biopsy, and all of them showed
minimal change nephropathy [19].
The definitions and criteria for nephrotic syndrome,
remission, and relapse were the same as those used by the
International Study of Kidney Disease in Children [19, 20].
Nephrotic syndrome was defined as urinary protein excre-
tion $ 40 mg/hr/m2 BSA with hypoalbuminemia (#25
g/liter). Remission was defined as a reduction in the urinary
excretion of protein to , 4 mg/hr/m2 BSA (Albustix, 0 to
trace) for three consecutive days. Relapse was denoted by
the reappearance of proteinuria $ 40 mg/hr/m2 (Albustix,
11 or greater) for three consecutive days.
Prednisolone was used as steroid therapy, the initial
attack being treated with 2 mg/kg per day prednisolone,
given in three divided doses (maximal dose 80 mg/day) for
the first four weeks, followed by alternate-day pred-
nisolone, with 1.3 mg/kg given as a single dose on the
morning of every other day for four weeks (total 8 weeks).
Relapses were treated with 2 mg/kg per day of prednisolone
given in three divided doses (maximal dose 80 mg/day) for
the first four weeks, followed by alternate-day prednisolone
with 2 mg/kg given as a single dose on the morning of every
other day for two weeks, after which dosage was decreased
by 0.5 mg/kg every two weeks (total 12 weeks).
The patients’ clinical data were collected retrospectively
from the medical records. Patients for whom accurate data
about the number of relapses were available were included
in the present study.
One hundred unrelated Japanese adult healthy volun-
teers from the same ethnic group (age range 21 to 55
years), without any history of renal disease and having
normal urine samples, were also studied as controls to
determine the population frequency of the gene mutation.
DNA analysis
Genomic DNA was extracted and purified from periph-
eral leukocytes in whole blood samples with a SepaGene kit
(Sanko, Tokyo, Japan). Polymerase chain reaction (PCR)
was performed according to a modification of the method
of Stafforini et al [17]. The genotype was determined by
three independent amplifications. The sequences of the
sense primer (Sense primer A) and three antisense primers
(Antisense primer B, C, D) were as follows:
Sense primer A: 59-CTATAAATTTATATCATGCTT-39
Antisense primer B: 59-TTTACTATTCTCTTGCTTTAC-39
Antisense primer C: 59-TCACTAAGAGTCTGAATAAC-39
Antisense primer D: 59-TCACTAAGAGTCTGAATAAA-39
The PCR was performed in a final volume of 30 ml, which
included DNA (100 ng), 103 buffer (3 ml), 50 mM MgCl2
(1.0 ml), 2.5 mM dNTP (2.35 ml) and 2.5 units Taq polymer-
ase (0.5 ml) (Perkin Elmer, New Jersey, USA). The reac-
tions were performed as follows: (a) one cycle for 10
minutes at 94°C; (b) 5 cycles for one minute at 94°C, one
minute at 56°C followed by one minute at 72°C; (c) 30
cycles for 30 seconds at 94°C, 30 seconds at 52°C followed
by 30 seconds at 72°C; (d) one cycle for five minutes at
72°C. The sizes of PCR products were: 160 bp with primers
A and B, and 108 bp otherwise. The products were
analyzed by electrophoresis on 3% agarose gels stained
with ethidium bromide.
The PCR products amplified by the sense primer A and
antisense primer B correspond to the whole of exon 9 of the
PAF acetylhydrolase gene. The PCR products amplified by
the sense primer A and antisense primer C correspond to a
part of exon 9 containing the normal sequence (G at
position 994). The PCR products amplified by sense primer
A and antisense primer D correspond to a part of exon 9
containing the mutation (T at position 994).
Assay for PAF acetylhydrolase activity
Plasma PAF acetylhydrolase activity was determined as
described by Miwa et al [16].
Statistical analysis
The results were analyzed with StatView J-4.02 or SPSS
6.xJ software [21, 22]. The associations of categorical
variables were examined by a chi-square test or Mantel-
Haenszel test. Continuous characteristics of the two geno-
type groups were compared using the Mann-Whitney U-
test. A two-tailed P value of less than 0.05 was considered
to be significant.
RESULTS
Analysis of the genotype and allele frequencies of the
PAF acetylhydrolase G994T gene mutation were per-
formed in the patients with SRNS and the control popula-
tion (Table 1). There was no significant difference in the
genotype and allele frequencies between patients with
SRNS and normal controls.
The clinical characteristics of patients with the GG
genotype and GT genotype are summarized in Table 2.
There was no significant difference between the two groups
with respect to the sex ratio, mean age of onset and mean
age at the time of study. However, the mean number of
relapses during the first year after onset was significantly
Table 1. Genotypes and allele frequencies of the platelet-activating
factor acetylhydrolase gene in controls and patients with steroid-
responsive nephrotic syndrome
N
Genotype Allele
GG GT TT G T
Controls 100 69 (69%) 30 (30%) 1 (1%) 0.84 0.16
Patients with 101 75 (74%) 26 (26%) 0 0.88 0.12
steroid-responsive
nephrotic syndrome
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higher in patients with the GT genotype than in those with
the GG genotype (Mann-Whitney U-test, P 5 0.0019). The
mean plasma PAF acetylhydrolase activity was significantly
lower in patients with the GT genotype than in those with
the GG genotype (Mann-Whitney U-test, P , 0.0001).
We therefore examined the distribution of relapse during
the first year after onset in patients with the GG genotype
and GT genotype (Table 3). The results showed that
patients with the mutant (GT) genotype had significantly
more relapses than those with the wild-type (GG) genotype
(Mantel-Haenszel test, X2 5 10.3, P 5 0.0012).
DISCUSSION
Studies in experimental animals indicate that PAF may
also be an important mediator of renal damage [23–26],
suggesting that its production and action in the kidney may
be regulated in disease states. It has been shown that
blockade of PAF receptors prevents proteinuria and glo-
merular injury in rabbit nephrotoxic nephritis [25]. Prelim-
inary studies have also been performed in human renal
diseases to evaluate the role of PAF [27–31]. Urinary and
plasma PAF was increased in children with SRNS and
levels correlated with disease activity [27]. Urinary PAF
was significantly higher in patients with membranous ne-
phropathy, and was positively correlated with proteinuria
[28]. PAF was increased in the urine of children with
hemolytic uremic syndrome, and levels correlated with
disease activity [29]. PAF receptor mRNA has been de-
tected in the kidney, being most abundant in the glomeru-
lus [32]. These results indicate that PAF has a potential
pathological role in glomerular injury. PAF acetylhydrolase
is widely distributed in plasma [12], blood cells and a variety
of tissues including the kidney [33]. It is also present in
urine [34]. PAF acetylhydrolase activity reflects the degree
of PAF-dependent reactions, and may also be a potential
candidate as a mediator of renal disease.
Recently, Tjoelker et al isolated the cDNA for human
plasma PAF acetylhydrolase and showed that the recombi-
nant enzyme abolishes PAF’s pathological actions [35].
They also showed that the inherited deficiency of PAF
acetylhydrolase in Japanese is the result of a point mutation
in exon 9 [17]. Patients with the mutant allele are likely to
have low PAF acetylhydrolase levels with an accumulation
of PAF. However, the functional significance of the muta-
tion in the PAF acetylhydrolase gene has not yet been
established in renal diseases.
It has been suggested that genetic factors may determine
susceptibility to SRNS. An association between some major
histocompatibility complex antigens and SRNS has been
described [36]. In the present study, the frequency in
normal controls of the GG, GT and TT genotypes for the
PAF acetylhydrolase gene was 69%, 30% and 1%, respec-
tively. These are similar to the frequency previously re-
ported in a Japanese population study (GG 69%; GT 27%;
TT 4%) [17]. There was no significant difference in the
genotype frequency between patients with SRNS and nor-
mal controls. These results indicate that there is no asso-
ciation between the PAF acetylhydrolase gene mutation
and the susceptibility to SRNS.
A characteristic feature of SRNS is its tendency to
relapse, the rate of which has been estimated to be between
40 and 90%. We have treated relapses with a 12-week
course of prednisolone during the first year after onset; this
treatment for relapse is popular among Japanese pediatri-
cians. We have used cyclophosphamide or cyclosporine as
adjuncts to prednisolone for inducing longer remissions in
children who have frequent relapses beyond the first year
after initial onset of nephrotic syndrome. We therefore
examined whether there was an association between the
PAF acetylhydrolase genotype and relapse during the first
year after the onset of nephrotic syndrome. Relapse is
considered a relevant event when assessing the prognosis of
SRNS. In the present study, the number of relapses defined
by the criteria of the International Study of Kidney Disease
in Children [19, 20] was significantly higher in patients with
the GT genotype than in those with the GG genotype. Of
the 75 patients with the GG genotype, 66% had either no or
one relapse, with only 8% having four or more relapses. In
contrast, only 30% of the 26 patients with the GT genotype
had either no or one relapse, while 35% had four or more
relapses. Weak evidence links SRNS with the major histo-
compatibility complex [37], but there is no marker that
correlates the frequency of relapse with the major histo-
compatibility complex in Japanese children. Although there
is an association between post-medication hypocortisolism
and relapse [38], there are no reliable clinical predictors of
the risk of subsequent relapse following the initial episode
Table 2. Clinical characteristics of patients with steroid-responsive
nephrotic syndrome according to the genotype at position 994 of the
platelet-activating factor acetylhydrolase gene
Genotype
GG
(N 5 75)
GT
(N 5 26) P
Age at onset years 6.3 6 3.7 6.1 6 4.0 0.69
Age at study years 11.1 6 4.6 11.1 6 4.2 0.85
M/F 52/23 20/6 0.46
Plasma PAF acetylhydrolase 1.81 6 0.61 0.88 6 0.51 , 0.0001
activity (nmol/min/50 ml)
Number of relapses 1.33 6 1.35 2.61 6 1.98 0.0019
during the one year from onset
Data are mean 6 SD except M/F.
Table 3. Number of relapses during the first year after onset according
to the genotype at position-994 of the platelet-activating factor
acetylhydrolase gene
Number of relapses during the one year from onset
0 1 2 3 $4
Genotype GG 25 (33%) 25 (33%) 8 (11%) 11 (15%) 6 (8%)
Genotype GT 4 (15%) 4 (15%) 6 (23%) 3 (12%) 9 (35%)
x2 5 10.3, p 5 0.0012 between genotype GG and GT groups.
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of SRNS. Assuming that our patients with SRNS are
representative of the whole population of Japanese chil-
dren with SRNS, analysis of the PAF acetylhydrolase gene
mutation in Japanese children with SRNS may allow iden-
tification of a group of patients with a predisposition to
relapse. Moreover, it is possible that therapy with a PAF
receptor antagonist may prevent relapses in patients with
SRNS.
The pathogenesis of SRNS is unknown. Shalhoub hy-
pothesized that T-cells release a factor(s) that damages the
glomerular basement membrane [39]. Although Shalhoub’s
hypothesis has not yet been proven, there is strong support
for the concept. For example, release of the lymphokine
called vascular permeability factor, which is produced by
activated lymphocytes from nephrotic subjects, when in-
jected intradermally causes increased permeability of the
vessels to macromolecules [40]. Recently Sirois and Edel-
man demonstrated that vascular permeability factor in-
creases vascular permeability by inducing PAF synthesis
[41]. Plasma PAF acetylhydrolase activity was significantly
lower in patients with the GT genotype than in those with
the GG genotype in the present study. It can therefore be
postulated that PAF accumulation due to a PAF acetylhy-
drolase deficiency will increase the permeability of the
glomerular basement membrane and permit relapse of
proteinuria in SRNS patients.
In summary, we have demonstrated an association be-
tween the PAF acetylhydrolase gene mutation and relapse
in SRNS. Our study suggests that PAF plays a significant
role in predisposing to relapse of SRNS. Additionally, it
also suggests that analysis of the PAF acetylhydrolase gene
mutation in Japanese children with SRNS may allow the
identification of a group patients who have a genetic
predisposition to relapse.
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